The addition of an antistaphylococcal beta-lactam to standard antibiotic therapy did not result in significant improvement for patients hospitalized with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, an international team of researchers reported today in JAMA.

The findings are from a randomized clinical trial conducted at 27 hospitals in four countries among patients hospitalized with MRSA bacteremia. The trial was stopped early because of safety concerns, as patients receiving combination therapy had significantly higher rates of acute kidney injury (AKI) than those who received standard therapy.

Credit: iStock Dr_Microbe

No significant improvement, higher kidney toxicity

Read more…